Welcome to our dedicated page for Inmune Bio SEC filings (Ticker: INMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to INmune Bio Inc. (NASDAQ: INMB) SEC filings, giving investors and researchers insight into the company’s clinical-stage biotechnology activities focused on the innate immune system. INmune Bio’s common stock is registered on The Nasdaq Stock Market LLC under the symbol INMB, and the company files periodic and current reports, proxy statements and other documents with the U.S. Securities and Exchange Commission.
Through Forms 10-K and 10-Q, users can review detailed discussions of INmune Bio’s DN-TNF platform (including XPro™/XPro1595), the CORDStrom™ human umbilical cord-derived mesenchymal stromal cell platform, and the INKmune® natural killer cell priming platform, along with risk factors, research and development expenses, and liquidity information. Current reports on Form 8-K document material events such as clinical trial updates, conference presentations, registered direct offerings, special stockholder meetings, option repricing approvals, and management or governance changes.
Definitive proxy statements on Schedule DEF 14A describe matters submitted to stockholders, including special meetings and proposals related to equity incentive plans. For capital markets activity, filings may include shelf registration statements, prospectus supplements and related exhibits describing registered direct offerings and placement agency agreements. Where applicable, Form 4 and other beneficial ownership reports provide information on insider transactions in INMB common stock.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping users interpret complex disclosures about clinical programs, financing arrangements and corporate actions. Real-time updates from EDGAR ensure that new INmune Bio filings are available as soon as they are posted, while AI tools highlight notable changes across annual reports, quarterly reports and 8-Ks so that readers can quickly focus on items most relevant to the DN-TNF, CORDStrom™ and INKmune® platforms.
INmune Bio, Inc. filed a Preliminary Proxy Statement for a 2025 Special Meeting to seek stockholder approval of two proposals: Proposal 1 to reprice certain outstanding stock options and Proposal 2 to adjourn the Special Meeting if necessary. The company will mail and post the Proxy Materials and allow virtual attendance; voting by Internet, telephone or proxy card is available and votes by mail must be received by November 17, 2025. The statement explains that underwater options reduce incentive value and that the Board believes repricing may help retain and motivate employees, officers and directors. The company discloses formulas for accounting under FASB ASC Topic 718 (recognize original grant fair value plus incremental fair value) and summarizes U.S. tax consequences for incentive and nonqualified options. Beneficial ownership disclosures show significant option and warrant holdings, including 1,174,549 option shares exercisable within 60 days for one holder and other named officers with option positions reported as of September 30, 2025.
INmune Bio Inc. reported that it has submitted a scientific manuscript for peer review describing results from its Phase 2 MINDFuL trial in early Alzheimer’s disease with inflammation. The manuscript, titled “XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial,” was submitted to npj Dementia, a Nature Portfolio journal. The company furnished a press release about this submission as an exhibit to the report.
INmune Bio (INMB) Form 3: Cory Randall Ellspermann, listed as a director and Interim CFO, reported beneficial ownership of stock options totaling 245,000 shares. The filing lists five option grants exercisable on dates between 11/24/2029 and 12/04/2034 with exercise prices from $3.91 to $21.06. One option is noted as fully vested and other grants include stated vesting schedules.
Highbridge Capital Management, LLC reported beneficial ownership of 1,454,400 shares of Inmune Bio, Inc. common stock that are issuable upon exercise of warrants. That amount represents 5.2% of the company's outstanding common stock on a base of 26,585,258 shares as stated in the issuer's prospectus, and the filing clarifies these shares are held by Highbridge-managed funds. The filing identifies Highbridge as a Delaware investment adviser and reports sole voting and dispositive power over the 1,454,400 shares. The statement asserts the securities were acquired in the ordinary course of business and not for the purpose of influencing control.
INmune Bio Inc. disclosure shows two reporting persons—CVI Investments, Inc. and its investment manager Heights Capital Management, Inc.—beneficially hold 1,396,279 shares represented by warrants. Those shares equal 4.9% of the outstanding common stock based on 26,585,258 shares reported outstanding as of June 30, 2025. The warrants include an anti-exercise limitation that prevents exercise to the extent ownership would exceed 4.99%.
The filing states neither reporting person has sole voting or dispositive power; voting and disposition are shared. Heights serves as investment manager to CVI and may exercise voting and dispositive power over the shares held by CVI, while each party disclaims beneficial ownership except for pecuniary interest.
Inmune Bio's Schedule 13G/A shows Praetorian-related entities holding disclosed positions in the company's common stock. Praetorian Capital Fund LLC directly beneficially owns 771,200 shares—comprised of 180,800 shares issuable upon warrants and 590,400 shares underlying call options exercisable within 60 days—representing approximately 2.9% of the class based on 26,585,258 shares outstanding. Mongolia (Barbados) Corp. directly owns 150,000 shares underlying call options (about 0.6%), and Harris Kupperman may be deemed to beneficially own a combined 921,200 shares (about 3.4%).
The filing identifies the reporting persons' roles (investment manager, manager, controlling person) and disclaims beneficial ownership beyond direct holdings. It specifies that reported positions include instruments exercisable within 60 days and includes a certification that the securities were not acquired to change or influence control of the issuer.